Method of prevention of egg drop syndrome - 76 birds

 

(57) Abstract:

The invention relates to veterinary medicine. The bird at the same time or within 24 hours after vaccination intramuscularly or intranasally administered soalan dose of 0.3-0.5 mg/kg body weight. Provides intense immunity and increase productivity. 5 table.

The invention relates to veterinary medicine, in particular to methods of prevention of adenovirus infections in birds and can be used for the prevention of egg drop syndrome - 76 (EDS ' 76) chickens.

Known methods of prevention of EDS ' 76 birds, including vaccines, mainly inactivated (1).

Known methods provide long-term (10 months) immunity with relatively high protective level.

The purpose of the invention is the enhancement of the prophylactic effectiveness of the method and the productivity of chickens.

This goal is achieved by the fact that the bird on the background of vaccination additionally enter product "Tolan" (Deltain).

"Tolan" (Deltain) is a natural, produced in the body regulatory nonapeptide with a stabilizing cellular homeostasis action, radical scavenging and membrane stabilizing action.

Research conducted on cows, calves, pigs, cats and dogs with non-communicable (rhinitis, bronchitis, nephritis, paresis, and paralysis of traumatic etiology and others), infectious diseases (distemper, leptospirosis, viral hepatitis, parvovirus enteritis, respiratory disease mixed virusbulletin etiology) and invasive (toxocariasis dogs) diseases, showed compatibility Solana" with various drugs and confirmed the possibility of its application in the background of the main schemes of treatment and prevention (2).

The method is as follows.

Chickens simultaneously with the introduction or 24 hours after administration of inactivated vaccine EDS ' 76 intranasally or intramuscularly soalan dose of 0.3-0.5 mg/kg body weight.

The proposed method meets the criterion of "novelty", as characterized by the presence of distinctive features of the prototype characteristics.

He also meets the criterion of "inventive step" as the set of distinctive features, which gives the object of the invention properties, providing a positive effect, available in s and the immune response, as well as the homeostasis of the organism as a consequence of increased synthesis of somatotropic hormone and inhibition of excessive production of corticosteroids.

Given that the reactivation of the pathogen EDS ' 76 occurs after reaching the contaminated bird full sexual maturity under the influence of stress caused by physiological changes in the body laying hens before the most active phase of egg-laying stress-protective action Solana in addition to immune modulating, enhances the protective level.

Research substantiating the parameters of the method and proving its effectiveness was conducted in conditions of Balakhna poultry (Nizhny Novgorod region) 110-day bird breed "ISA-brown.

The essence of the method is illustrated by examples.

Example 1. The rationale for the dose. Formed 5 groups of hens were kept in identical conditions on the same diet. Chickens of all groups were vaccinated against EDS ' 76 intramuscular in the right thigh by the introduction of liquid inactivated vaccine "Osize" in a dose of 0.5 ml at the same time in the first 4 groups intramuscularly in the left thigh was introduced soalan dose of 0.3, and 0.4, 0.5, and 0.6 mg/kg body weight. Efficacy was assessed FDI (RZGA) on the 21st day after vaccination. Take into account the clinical condition of the birds and the reaction to the introduction Solana. The results are presented in table 1.

As can be seen from table 1, the indicators of intensity of immunity in experimental groups, regardless of the dose Solana higher than in the control, but higher doses are not economically feasible, as it was discovered the tendency to decrease compared with optimal doses (groups 2 and 4).

Example 2. Rationale as a way of introduction. Formed 4 groups of chickens, which were kept in the same conditions on the same diet. Chickens of all groups were vaccinated as in example 1. 24 hours after vaccination in the first 3 groups were used soalan at a dose of 0.4 mg/kg body weight: in the 1st group intramuscularly in the left thigh, in the 2nd and 3rd groups intranasal spray method krupeckaite, and in group 2 - drug soalan not stabilized by glycerol, and in the 3rd group is a drug soalan stabilized by glycerol at the rate of 10% of the solution volume.

Efficacy was evaluated as in example 1. The results are presented in table 2.

As can be seen from table 2, in the experimental groups the indicators of intensity of immunity is significantly higher than in control. Due to the simplicity of implementation is preferred in glicerina at the rate of 10% of the solution volume.

Example 3. The justification for the introduction. Formed 3 groups of hens were kept in identical conditions on the same diet. Chickens of all groups were vaccinated as in example 1. In the first two groups intranasal spray method was used soalan stabilized with glycerol at the rate of 10% of the volume of the solution, at a dose of 0.4 mg/kg body weight, in 1-St group - 24 hours after vaccination, in the 2nd group - together with the vaccination. Efficacy was evaluated as in example 1. The results are presented in table 3.

As can be seen from table 3, the introduction Solana had no effect on the indicators of intensity of the immune system relative to the control group, the best performance is obtained with the simultaneous introduction of the vaccine and Solana. Simultaneous vaccine introduction Solana is preferred.

Example 4. Confirmation of effectiveness. Formed 6 groups of hens were kept in identical conditions on the same diet. In 3 groups prevention of EDS '76 carried out by known methods with the use of inactivated vaccines (Osize, vaccines made ARRIAH, vaccine Unuversity (France) against infectious bronchitis, Newcastle disease and EDS' 76) in the other 3 groups - offer way, stabilizirovannogo glycerol at the rate of 10% of the volume of the solution, at a dose of 0.8 ml simultaneously with the introduction of the vaccine. Additionally, given the intensity of the immune system took into account the productivity of the increase in live weight at 70 days and egg productivity for 31 days.

The results are presented in tables 4 and 5.

As can be seen from tables 4 and 5, the proposed method provides significant improvements tension immunity (as a geometric average antibody titers were increased 1.4-2.6 times) and productivity, which confirmed the effectiveness of the proposed method.

The proposed method is feasible and effective in intramuscular or intranasal simultaneously with the vaccine or 24 hours after its introduction the use of Solana regardless of the vaccine.

Preferred is the simultaneous vaccine intranasal spray method introduction Solana.

Established tolerability Solana regardless of method of administration, which was confirmed by the absence of local skin reactions in intramuscular and normal work of breathing by intra. Mobility behaviour, the palatability of feed and reaction to external stimuli near BR> 1. R. N. Korovin, I. K. Christmas. Adenoviral infection of poultry.- M: Agropromizdat, 1990, S. 49-72.

2. Veterinary practice, N 3, 1997, S. 22-29.4

Method of prevention of egg drop syndrome-76 birds by introducing a vaccine, characterized in that at the same time or within 24 hours after vaccination intramuscularly or intranasally administered soalan dose of 0.3 - 0.5 mg/kg body weight.

 

Same patents:

The invention relates to the field of veterinary medicine, in particular to poultry, namely vaccines against infectious diseases, namely virus of egg drop Syndrome-76 (EDS ' 76), and methods of vaccination
The invention relates to the field of biotechnology and veterinary Virology and concerns the means of specific prophylaxis and treatment of diseases of carnivores, in particular, to means of specific prophylaxis of plague, parvovirus enteritis, adenoviral infection and infectious hepatitis
The invention relates to the field of veterinary Virology and biotechnology and can be used in the production of antigen and immune serum for setting the neutralization with the aim of laboratory diagnostics of hydropericardium birds
The invention relates to medicine, namely to obstetrics, and can be used in the treatment of severe forms of preeclampsia and eclampsia

The invention relates to medical equipment, inhalation devices and methods of inhalation

The invention relates to medicine, namely to pharmacology, and relates to means for the treatment of inflammatory diseases of female genitals

The invention relates to the field of biotechnology

The invention relates to medicine, in particular to Infectology

The invention relates to a method for producing water-soluble conjugates (or their salts) polymyxin b B (PMB) or their salts and acid by the interaction of polymyxin b B or its salt with the acid in an aqueous medium at a pH of from about 9.3 to about 10, preferably from about 9.5 to about 9,7, and a temperature of from about 30oC to about 35oC, preferably about 32oC

The invention relates to novel antagonists of LH-RF, and above all, peptidomimetics and peptide with a modified side chain, of the formula V, where D-Xxx, R1- R8described in the description, and their salts with pharmaceutically acceptable acids, as well as it describes their therapeutic use as analogue releasing factor, luteinizing hormone (LH-RF) with high antagonistic activity and not detecting unwanted side effects, especially no incentive edema

FIELD: medicine, cardiology.

SUBSTANCE: the suggested method should be performed at the background of medicinal therapy with preparations out of statins group, tevetene, polyoxidonium and conducting seances of plasmapheresis by removing 800 ml plasma twice weekly with N 5 due to additional intramuscular injection of immunophan 0.005%-1.0 with N 10 and fluimucyl 300 mg intravenously daily with N 5-10, total course of therapy lasts for 2 mo. The method provides modulation of leukocytic functional activity, moreover, due to altered cytokine profile and, thus, through disintegration of protein-lipid complexes participating in the development of atherosclerotic platelets.

EFFECT: higher efficiency of therapy.

3 ex

FIELD: medicine, phthisiology, anesthesiology.

SUBSTANCE: during the day of operation one should perform autohemotransfusion, then introduce epocrine intravenously by drops at the dosage of 50-200 U/kg patient's body weight; next day after interference one should inject epocrine subcutaneously at the dosage of 25-100 U/kg; at hematocrit level being below 35% 48 h after operation it is necessary to repeat subcutaneous injection of the above-mentioned preparation at the dosage not exceeding 50 U/kg. The present innovation favors hemopoiesis stimulation in postoperational period, that, in its turn, accelerates postoperational rehabilitation in patients of this group and enables, also, to avoid allotransfusions being dangerous because of immunoconflicting reactions.

EFFECT: higher efficiency of compensation.

1 ex, 1 tbl

FIELD: pharmaceutical chemistry, medicine.

SUBSTANCE: in the suggested composition one should apply heptapeptide of Met-Glu-His-Phe-Pro-Gly-Pro sequence (heptapeptide A) for treating ischemic insult due to introducing 2 drops of compositions into each nasal canal 5-6 times daily for 10 d at disease of average severity degree, and in case of severe degree - per 3 drops of the present composition into each nasal canal 7 times daily for 10 d. The present innovation provides increased efficiency at decreased concentration of heptapeptide without any side effects.

EFFECT: higher efficiency of therapy.

2 cl, 6 dwg, 8 ex, 5 tbl

FIELD: genetic engineering, medicine.

SUBSTANCE: invention relates to T-cell receptor sequence being detected in patients with extended sclerosis and is useful in diagnosis and therapy. Oligonucleotide including sequence which represents or is derived from 5'-CTAGGGCGGGCGGGACTCACCTAC-3' or nucleotide sequence being fully complementary thereto. Oligonucleotide together with nuclear acid including nearly 15-30 oligonucleotides, which doesn't comprise oligonucleotide sequence and presents in region from Vβ to Jβ of Vβ13.1 gene in T-cell Vβ13.1-subgroup, wherein oligonucleotide and nuclear acid sequences don't present in the same chain of pair sequences of Vβ13.1 gene, is used in Vβ13.1 gene part amplification. In method for detection of LGRAGLTY motive, which is present in T-cell receptors of T-cell Vβ13.1-subgroup, oligonucleotide is used in combination with labeling particle. Once LGRAGLTY motive is detected, development monitoring and treatment are carried out by removing of LGRAGLTY motive-containing peptide.

EFFECT: simplified methods for detection of LGRAGLTY motive in T-cell receptors and treatment of patients with extended sclerosis.

21 cl, 7 dwg, 3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: peptide of the following formula: X-Pro-Gly-P, where X = Thr-Lys-Pro-Arg-; Lys-pro-Arg-; pro-Arg-; Arg-, being of untiulcerous activity. They should be applied at intraperitoneal injection at the dosage of 0.58-3.20 mcM g/kg for preventing and treating ulcers of gastro-intestinal tract.

EFFECT: higher efficiency and prophylaxis.

4 dwg, 5 ex

Up!